Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 10;39(7):966-970.
doi: 10.3760/cma.j.issn.0254-6450.2018.07.019.

[Analysis on 10 year survival of HIV/AIDS patients receiving antiretroviral therapy during 2003-2005 in Henan province]

[Article in Chinese]
Y Sun  1 , Q X Zhao, C F Li, X Yang, X Zhang, C L Liu, Z Y Chen
Affiliations

[Analysis on 10 year survival of HIV/AIDS patients receiving antiretroviral therapy during 2003-2005 in Henan province]

[Article in Chinese]
Y Sun et al. Zhonghua Liu Xing Bing Xue Za Zhi. .

Abstract
in English, Chinese

Objective: To understand the survival of HIV/AIDS patients after receiving antiretroviral therapy for 10 year in Henan province and related factors. Methods: The database of national integrated management system of HIV/AIDS was used to collect the basic information and follow-up information of HIV/AIDS patients who received antiretroviral therapy between 2003 and 2005 in Henan province. Software SPSS 23.0 was used to analyze the patients' survival and related factors based on the life-table method and Cox proportional hazards model. Results: Among the 2 448 HIV/AIDS patients who started antiretroviral therapy during 2003-2005, the men accounted for 53.5%, and women accounted for 46.5%. Up to 70.1% of the patients were aged 40-59 years and 95.5% of the patients had blood borne infections. The patients were observed for 10 years after antiviral treatment, and 719 cases died from AIDS related diseases, with a mortality rate of 3.78/100 per year (719/19 010 per year). The cumulative survival rates of patients within 1-year, 3 years, 5 years and 10 years were 0.94, 0.86, 0.78, 0.69 respectively. Compared with the patients aged <40 years, the HRs of the patients aged 40-, 50-, 60- and ≥70 years were 1.417 (95%CI: 0.903-2.222), 1.834 (95%CI: 1.174-2.866), 2.422 (95%CI: 1.539-3.810) and 3.424 (95%CI: 2.053-5.709) respectively. Compared with patients with baseline CD(4+)T lymphocyte >350 unit/ul, the HRs of the patients with CD(4+)T lymphocyte <50 unit/μl, 50-199 unit/ul and 200-350 unit/ul were 7.105 (95%CI: 5.449-9.264), 4.175 (95%CI: 3.249-5.366) and 2.214 (95%CI: 1.691-2.900) respectively. Compared with the women, the HR of the men was 1.480 (95%CI: 1.273-1.172). Compared with the patients who received second line ART therapy, the HR of patients receiving no second line therapy was 11.923 (95%CI: 9.410-15.104). Conclusions: The cumulative survival rate the HIV/AIDS patients after 10 years of antiretroviral therapy reached 0.69 in Henan. Male, old age, low basic CD(4+)T lymphocyte count and receiving no second line therapy were the risk factors for long-term survival of AIDS patients.

目的： 分析河南省艾滋病感染者和艾滋病患者（HIV/AIDS）抗病毒治疗（antiretroviral therapy，ART）10年生存状况及影响长期生存的因素。 方法： 利用国家艾滋病抗病毒治疗数据库，收集河南省2003－2005年接受ART的HIV/AIDS基本情况和治疗随访信息，采用寿命表法和Cox比例风险模型分析生存状况和影响长期生存的危险因素，采用SPSS 23.0软件进行统计分析。 结果： 2003－2005年开始ART的2 448例HIV/AIDS中，男性占53.5%（1 309/2 448），女性占46.5%（1 139/2 448），40~59岁占70.1%（1 715/2 448），以血液传播为主，占95.5%（2 337/2 448）；ART后随访10年，死于艾滋病及相关疾病719例，死亡率为3.78/100人年（719/19 010人年）；患者第1、3、5、10年累计生存率为0.94、0.86、0.78、0.69。相对于年龄<40岁组，40~、50~、60~和≥70岁组HR值（95%CI）分别为1.417（0.903~2.222）、1.834（1.174~2.866）、2.422（1.539~3.810）和3.424（2.053~5.709）；相对于基线CD(4+)T淋巴细胞（CD(4)）>350个/μl，CD(4)<50、50~199、200~350个/μl的HR值（95%CI）值分别为7.105（5.449~9.264）、4.175（3.249~5.366）和2.214（1.691~2.900）；男性相对于女性HR=1.480（95%CI：1.273~1.172）、没有更换二线治疗HR=11.923（95%CI：9.410~15.104）。 结论： 河南省早期HIV/AIDS接受ART 10年后的累计生存率为0.69，男性、年龄较大、基线CD(4)水平低、未及时更换二线抗病毒药物为影响其长期生存的危险因素。.

Keywords: Antiretroviral therapy; HIV/AIDS; Influencing factors; Long-term; Survival analysis.

PubMed Disclaimer